14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Monday, 6th May 2024 MDGL stock ended at $235.57. This is 2.49% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 3.58% from a day low at $228.48 to a day high of $236.65.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Aug 24, 2023 $179.74 $180.02 $175.33 $177.27 162 742
Aug 23, 2023 $182.00 $182.23 $178.22 $179.20 309 934
Aug 22, 2023 $178.87 $184.73 $174.05 $180.89 150 907
Aug 21, 2023 $179.64 $182.79 $177.55 $179.37 185 091
Aug 18, 2023 $171.75 $180.90 $171.00 $179.74 242 235
Aug 17, 2023 $175.99 $177.50 $172.46 $174.00 237 515
Aug 16, 2023 $173.83 $176.21 $171.50 $175.61 193 970
Aug 15, 2023 $172.01 $177.71 $166.65 $174.17 271 844
Aug 14, 2023 $170.15 $175.82 $168.50 $173.44 296 704
Aug 11, 2023 $170.83 $172.81 $167.34 $171.43 190 310
Aug 10, 2023 $169.31 $174.09 $168.01 $171.71 224 930
Aug 09, 2023 $168.98 $172.72 $162.76 $168.73 339 570
Aug 08, 2023 $175.00 $175.00 $156.02 $169.06 925 983
Aug 07, 2023 $194.81 $194.81 $178.79 $179.49 350 488
Aug 04, 2023 $194.94 $195.24 $190.10 $194.48 179 479
Aug 03, 2023 $196.04 $197.44 $190.54 $193.27 254 714
Aug 02, 2023 $200.02 $201.52 $195.36 $198.47 225 084
Aug 01, 2023 $204.75 $205.10 $200.43 $202.32 207 872
Jul 31, 2023 $204.46 $208.00 $202.60 $205.30 228 260
Jul 28, 2023 $201.00 $206.62 $200.00 $205.51 197 388
Jul 27, 2023 $203.15 $203.30 $198.03 $199.92 250 083
Jul 26, 2023 $209.54 $212.40 $201.17 $201.34 254 515
Jul 25, 2023 $205.68 $211.25 $205.02 $210.63 195 744
Jul 24, 2023 $214.97 $216.10 $203.85 $205.68 207 589
Jul 21, 2023 $213.94 $217.19 $212.75 $215.75 158 687
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT